Company Overview and News

 
Ellis starts new race where she left off - in first place

2018-04-14 smh.com.au
Straight after winning the last Shares Race, Angie Ellis of 80 20 Investments starts the new four-week race in the lead, with her original $100,000 portfolio worth $108,192.
Upvote Downvote

 
Novatti Group launches service for Chinese to pay Australian bills, shares surge

2018-04-06 proactiveinvestors.com.au
Novatti Group Ltd (ASX:NOV) is a leading ASX gainer after launching its chinapayments.com payment service allowing Chinese residents to pay Australian bills using funds from their Alipay e-wallet.
Upvote Downvote

 
Novatti Group teams with Chinese fintech company to progress blockchain opportunities

2017-12-12 proactiveinvestors.com.au
Novatti Group Ltd (ASX:NOV) has entered into a memorandum of understanding (MoU) with Shanghai Gingkoo Financial Technology Co Ltd.
Upvote Downvote

 
Novatti Group to lifts funds following integration of Bitcoin service

2017-10-09 proactiveinvestors.com.au
Novatti Group Ltd (ASX:NOV) is a global software technology and payment services provider, and last month outlined that one of its Software as a Service client is ready for a commercial launch and is integrating a Bitcoin exchange to the Novatti Payments Platform.
Upvote Downvote

 
Novatti Group launches innovative overseas fund remittance service

2017-08-04 proactiveinvestors.com.au
Novatti Group (ASX:NOV) has launched a remittance operation to service Australian retail consumers and small businesses that need to send funds overseas.
Upvote Downvote

 
Novatti Group gets set to pounce

2017-05-04 proactiveinvestors.com.au
Novatti Group (ASX:NOV) has some acquisition news pending, with the ASX granting the company a trading halt to prepare.
Upvote Downvote

 
Novatti Group launches payment product in Scandinavia

2017-03-28 proactiveinvestors.com.au
Novatti Group (ASX:NOV) has partnered with Sweden-based PayGround AB to launch an electronic payment product in the Scandinavian market.
Upvote Downvote

1
Transaction Solutions International to focus on services for India

2017-02-12 proactiveinvestors.com.au
Transaction Solutions International (ASX:TSN) (TSI) and Novatti Group (ASX:NOV) are planning to jointly develop a range of mobile and online payment services designed specifically for the Indian market.
Upvote Downvote

 
Novatti Group Ltd unlocks prospectus milestone performance shares

2016-09-16 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

 
Novatti Group Ltd to support WeChat payments in Australia

2016-09-06 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

 
 
Quarterly Report

2016-04-29 asx.com.au
Upvote Downvote

 
Novatti Group gains new contract, revenue from Tanzanian telco

2016-04-26 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...